They are hardly at the top of the ladder, and its only the start...

They are hardly at the top of the ladder, and its only the start of the season. They have multiple phase 1 trials to complete, then its on to ph2, and possibly phase 3. This is a multi year play, and they need to keep the funding alive. When you look at her tenure, she's been the CEO of a company that seen its share price go from over 30c to under 3c. I know it's not entirely her fault, but in this biotech winter they've been hit hard, and as a CEO, you are required to take some responsibility. It was not sustainable for a company this small to be paying someone that much in wages. Her commitments to the CR was abysmal. She spoke a good pitch but ultimately her actions (ownership) was saying other things. I respect her but I think ultimately she has done her service here and has been rewarded handsomely. Onwards we go!